Windtree Therapeutics (WINT)
OTHER OTC:WINT
Top Page
Windtree Therapeutics
(OTC:WINT)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.01
▼(-56.67% Downside)
Action:ReiteratedDate:02/04/26
The score is dragged down primarily by very weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity with higher debt), reinforced by strongly bearish technical signals (well below moving averages with negative momentum). Valuation provides limited offset because losses make P/E uninformative and there is no dividend yield support.
Positive Factors
Focused critical-care biotech pipeline
Specialization in critical‑care and cardiopulmonary therapeutics is a durable strategic position: these are high‑unmet‑need areas with structural demand and limited crowded competition. A successful clinical advance could produce outsized long‑term returns relative to company size.
Negative Factors
Negative equity and rising leverage
Negative equity and increased debt signal materially impaired balance‑sheet resilience. With equity deficit and higher leverage, the company faces elevated insolvency, refinancing and dilution risks, reducing financial flexibility to fund clinical programs long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused critical-care biotech pipeline
Specialization in critical‑care and cardiopulmonary therapeutics is a durable strategic position: these are high‑unmet‑need areas with structural demand and limited crowded competition. A successful clinical advance could produce outsized long‑term returns relative to company size.
Read all positive factors
Windtree Therapeutics (WINT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$394.39K
Dividend YieldN/A
Average Volume (3M)403.29K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth99.09%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,708,782
10 Day Avg. Volume496,404
30 Day Avg. Volume403,289
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.06
Enterprise Value/Market Cap33.26
Enterprise Value/Revenue145.76
Enterprise Value/Gross Profit1.19K
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-549
Revenue Forecast (FY)$12.40M
Windtree Therapeutics Business Overview & Revenue Model
Company Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs incl...
How the Company Makes Money
Windtree Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products, including licensing agreements and collaboration partnerships. The company may receive milestone payments, roy...
Windtree Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
7
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.00K | -84.00K | -82.00K | -1.06M | -869.00K | -638.00K |
| EBITDA | -42.60M | -1.47M | -20.16M | -39.46M | -76.64M | -31.80M |
| Net Income | -40.00M | -5.49M | -20.29M | -39.21M | -67.64M | -30.28M |
Balance Sheet | ||||||
| Total Assets | 15.98M | 27.88M | 32.41M | 37.95M | 74.79M | 112.89M |
| Cash, Cash Equivalents and Short-Term Investments | 204.00K | 1.78M | 4.32M | 6.17M | 22.35M | 16.93M |
| Total Debt | 12.93M | 1.82M | 16.83M | 2.28M | 2.89M | 3.78M |
| Total Liabilities | 27.58M | 17.88M | 29.02M | 27.94M | 32.91M | 43.33M |
| Stockholders Equity | -11.61M | 10.00M | 3.39M | 10.01M | 41.88M | 69.55M |
Cash Flow | ||||||
| Free Cash Flow | -15.12M | -15.41M | -13.45M | -19.46M | -23.94M | -25.61M |
| Operating Cash Flow | -15.12M | -15.40M | -13.44M | -19.45M | -23.66M | -25.32M |
| Investing Cash Flow | -5.97M | -12.00K | -15.00K | 197.00K | -279.00K | -291.00K |
| Financing Cash Flow | 19.00M | 12.73M | 11.60M | 3.08M | 29.36M | 19.96M |
Windtree Therapeutics Technical Analysis
Negative
0.03
Price Trends
0.01
Negative
0.03
Negative
0.21
Negative
Market Momentum
>-0.01
Negative
44.12
Neutral
10.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.
Windtree Therapeutics Risk Analysis
Windtree Therapeutics disclosed 83 risk factors in its most recent earnings report. Windtree Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Windtree Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $13.63M | -0.10 | -209.36% | ― | ― | 83.25% | |
46 Neutral | $4.84M | -0.22 | 1937.42% | ― | ― | -22.52% | |
43 Neutral | $3.81M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $3.52M | -0.13 | -317.98% | ― | ― | 34.57% | |
42 Neutral | $3.70M | -0.10 | -262.78% | ― | ― | 79.45% | |
39 Underperform | $394.39K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
WINT
Windtree Therapeutics
0.01
-1.32
-99.17%
TOVX
Theriva Biologics
0.30
-0.75
-71.71%
INDP
Indaptus Therapeutics
1.57
-12.63
-88.94%
ENVB
Enveric Biosciences
1.96
-12.56
-86.50%
ARTL
Artelo Biosciences
6.84
-9.72
-58.69%
AZTR
Azitra Inc
0.24
-1.63
-87.39%
Windtree Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Windtree Therapeutics Announces Sudden Departure of President and COO
Negative
Jan 7, 2026
On January 5, 2026, Windtree Therapeutics, Inc. announced that Eric L. Curtis resigned from his roles as President and Chief Operating Officer, effective immediately. The abrupt leadership change may signal a period of transition for the company&#...
M&A TransactionsPrivate Placements and Financing
Windtree Therapeutics Issues Convertible Notes for Acquisition
Neutral
Dec 2, 2025
On November 25, 2025, Windtree Therapeutics issued $857,142.86 in senior convertible promissory notes due 2026 to fund the acquisition of CommLoan Inc. and for corporate purposes. The notes, which mature in 2026, include provisions for conversion ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.